Study sugg

Study suggests patients on anti-CD20 treatment able to mount potent T-cell responses following mRNA COVID-19 vaccination

Patients on anti-CD20 treatment are able to mount potent T-cell responses to mRNA coronavirus disease 2019 (COVID-19) vaccines, despite impaired humoral responses, according to a study published in Clinical Infectious Diseases. For the study, Natacha Madelon, University of Geneva, Geneva, Switzerland, and colleagues assessed humoral and T-cell responses in 37 patients treated with either ocrelizumab for multiple sclerosis (MS; n = 26) or rituximab for rheumatic diseases (n = 11) compared to 22 age-matched immunocompetent individuals after completion of 2 doses of mRNA-based COVID-19 vaccine...

EMA recommends approval of Comirnaty COVID-19 vaccine for children aged 5 to 11

The European Medicines Agency (EMA) announced that its Committee for Medicinal Products for Human Us...

Neonatal acute kidney injury: a case-based approach

Neonatal acute kidney injury (AKI) is increasingly recognized as a common complication in critically


Suggested videos

Search:
Date
Filters:
Associatio
2:59

Associations of hypoglycaemia and glycaemic variability with cardiac arrhythmias using a long-term monitoring approach in insulin-treated patients with type 2 diabetes

Presenter: Andreas Andersen
Diabetology : Diabetes
EASD 2021
The role o
4:35

The role of SGLT2 inhibitors in the treatment of diabetes with cardiovascular disease

Presenter: Mikael Rydén
Diabetology : Diabetes
EASD 2021
The curren
14:50

The current issues in Hypoglycaemia

Presenter: Brian Frier
Diabetology : Diabetes
EASD 2021
Current gu
12:05

Current guidelines on diabetes management

Presenter: Christoph Wanner
Diabetology : Diabetes
EASD 2021
Spotlight
16:53

Spotlight on the emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)

Presenter: Peter Galle
Oncology
ESMO 2021
The MONALE
8:37

The MONALEESA-2 trial

Presenter: Gabriel N. Hortobagyi
Oncology
ESMO 2021
Should Cur
16:32

Should Cure Be A Reasonable Goal in aRCC?

Presenter: David F. McDermott
Oncology
ESMO 2021
Is Unresec
6:32

Is Unresectable Malignant Pleural Mesothelioma a New Frontier for I-O?

Presenter: Alessandra Curioni-Fontecedro
Oncology
ESMO 2021
The Keynot
7:05

The Keynote 716 trial

Presenter: Jason J. Luke
Oncology
ESMO 2021
Navigating
5:56

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Judy King
Oncology
ESMO 2021
Metastases
7:04

Metastases-free survival results from STAMPEDE trial

Presenter: Gerhardt Attard
Oncology
ESMO 2021
Navigating
5:19

Navigating a New Era in HER2+ Metastatic Breast Cancer: Focus on HER2CLIMB

Presenter: Wolfgang Janni
Oncology
ESMO 2021
Highlights
10:39

Highlights of the ESMO 2021 Congress

Presenter: Solange Peters
Oncology
ESMO 2021
SSaSS: Sal
3:42

SSaSS: Salt Substitute and Stroke Study into the effect of salt substitutes on cardiovascular events and death

Presenter: Bruce Neal
Cardiology
ESC 2021
2021 ESC G
7:39

2021 ESC Guidelines - CVD Prevention

Presenter: Frank Visseren
Cardiology
ESC 2021
The digita
11:38

The digital age: The future of respiratory medicine

Presenter: Henry Chrystyn
Respiratory
ERS 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The role o
10:22

The role of GLP-1 receptor agonists in weight reduction and cardiovascular risk reduction

Presenter: Michael A. Nauck
Cardiology , Diabetology
Clinical I
9:00

Clinical Impact of Liraglutide as a Treatment of Obesity

Presenter: Alexander Miras
Cardiology , Diabetology